These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24666591)

  • 21. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial.
    Middleton S; McElduff P; Ward J; Grimshaw JM; Dale S; D'Este C; Drury P; Griffiths R; Cheung NW; Quinn C; Evans M; Cadilhac D; Levi C;
    Lancet; 2011 Nov; 378(9804):1699-706. PubMed ID: 21996470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ultrasound assisted thrombolysis in acute ischaemic stroke: preliminary experience in Singapore.
    Sharma VK; Rathakrishnan R; Ong BK; Chan BP
    Ann Acad Med Singap; 2008 Sep; 37(9):778-82. PubMed ID: 18989495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A citywide prehospital protocol increases access to stroke thrombolysis in Toronto.
    Gladstone DJ; Rodan LH; Sahlas DJ; Lee L; Murray BJ; Ween JE; Perry JR; Chenkin J; Morrison LJ; Beck S; Black SE
    Stroke; 2009 Dec; 40(12):3841-4. PubMed ID: 19875743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Collaborative Interventions Reduce Time-to-Thrombolysis for Acute Ischemic Stroke in a Public Safety Net Hospital.
    Threlkeld ZD; Kozak B; McCoy D; Cole S; Martin C; Singh V
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):1500-1505. PubMed ID: 28396187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.
    Xian Y; Xu H; Lytle B; Blevins J; Peterson ED; Hernandez AF; Smith EE; Saver JL; Messé SR; Paulsen M; Suter RE; Reeves MJ; Jauch EC; Schwamm LH; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28096207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementing evidence-based recommended practices for the management of patients with mild traumatic brain injuries in Australian emergency care departments: study protocol for a cluster randomised controlled trial.
    Bosch M; McKenzie JE; Mortimer D; Tavender EJ; Francis JJ; Brennan SE; Knott JC; Ponsford JL; Pearce A; O'Connor DA; Grimshaw JM; Rosenfeld JV; Gruen RL; Green SE;
    Trials; 2014 Jul; 15():281. PubMed ID: 25012235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
    Lorenzano S; Toni D;
    Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protocol adherence and safety of intravenous thrombolysis after telephone consultation with a stroke center.
    Uchino K; Massaro L; Jovin TG; Hammer MD; Wechsler LR
    J Stroke Cerebrovasc Dis; 2010; 19(6):417-23. PubMed ID: 21051004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombolysis for acute ischaemic stroke.
    Wardlaw JM; Murray V; Berge E; Del Zoppo GJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD000213. PubMed ID: 19821269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke.
    Yeo LL; Paliwal P; Teoh HL; Seet RC; Chan BP; Wakerley B; Liang S; Rathakrishnan R; Chong VF; Ting EY; Sharma VK
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e590-6. PubMed ID: 23954601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perfusion computed tomography to assist decision making for stroke thrombolysis.
    Bivard A; Levi C; Krishnamurthy V; McElduff P; Miteff F; Spratt NJ; Bateman G; Donnan G; Davis S; Parsons M
    Brain; 2015 Jul; 138(Pt 7):1919-31. PubMed ID: 25808369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reperfusion and outcomes in Penumbra vs. systemic tissue plasminogen activator clinical trials.
    Alexandrov AV; Schellinger PD; Saqqur M; Barreto A; Demchuk AM; Ribo M; Rubiera M; Sharma VK; Heliopoulos I; Alexandrov AW; Molina CA; Tsivgoulis G;
    Int J Stroke; 2011 Apr; 6(2):118-22. PubMed ID: 21371272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.
    Adelman EE; Scott PA; Skolarus LE; Fox AK; Frederiksen SM; Meurer WJ
    J Stroke Cerebrovasc Dis; 2016 Jan; 25(1):67-73. PubMed ID: 26419527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis.
    Stroke Thrombolysis Trialists' Collaborative Group
    Int J Stroke; 2013 Jun; 8(4):278-83. PubMed ID: 23639145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: an audit of current practice and clinical outcomes.
    Williams JM; Navin TJ; Jude MR; Levi CR
    Aust J Rural Health; 2013 Aug; 21(4):203-7. PubMed ID: 24033520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombolysis for acute stroke in Australia: outcomes from the Safe Implementation of Thrombolysis in Stroke registry (2002-2008).
    Simpson MA; Dewey HM; Churilov L; Ahmed N; Bladin CF; Schultz D; Markus R; Sturm JW; Levi CR; Blacker DJ; Jannes J; Lindley RI; Parsons MW
    Med J Aust; 2010 Oct; 193(8):439-43. PubMed ID: 20955119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.